Achiko AG reports first half to 30 June 2022 results and provides corporate update as of 30 September 2022

Achiko AG / Key word(s): Half Year Results Achiko AG reports first half to 30 June 2022 results and provides corporate update as of 30 September 2022 03-Oct-2022 / 03:05 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.  Achiko AG reports first half to 30 June 2022 results and provides corporate update as of 30 September 2022

• Achiko reports an EBITDA loss of USD 1.9 million, compared to an EBITDA loss of USD 4.6 million for the 6 months ending 30 June 2021.
• Focal points of the first half year were completion of a major new sales contract in Indonesia, obtaining a CE Mark for AptameX and streamlining the organisation ahead of launching and scaling production for sales to Indonesia and other countries.
• AptameX, Achiko’s proprietary low-cost, saliva-based Covid-19 diagnostic, has shown competitive product performance to other Covid-19 testing solutions with calibration testing confirming its ability to deliver a >97% sensitive and >97% specific rapid test at a wider range of viral loads than most other rapid tests.
• After the balance sheet date, raised CHF 1.25 million in financing with sophisticated investors.

Zurich, 3 October 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company) is pleased to announce its financial results for the period of 6 months to 30 June 2022, and its progress since then which can be found at https://www.achiko.com/financials.

In the first half of 2022, Achiko AG has confirmed that calibration testing of its affordable non-invasive Covid-19 saliva-based rapid test technology, AptameX^TM, indicated the system’s ability to deliver a >97% sensitive and >97% specific rapid test at a wider range of viral loads than most other rapid tests.

“The ability to offer healthcare professionals a practical alternative to PCR tests and less accurate antigen based rapid tests has been a major driver for Achiko’s research and clinical development teams to produce the world’s first scale application using DNA aptamers in a commercial diagnostic setting”, said Mr Steven Goh, CEO of Achiko. “The use of differentiated chemistry to develop a range of non-invasive, highly accurate, and cost-effective rapid tests with Achiko’s AptameX technology, positions the Company at the leading edge of diagnostic development moving forward.”